1Sager PT.New advances in class Ⅲ antiarrhythmic drug therapy.Curr Opin Cardiol,2000,15:41-53.
2Greenbaum RA,Campbell TJ,Channer KS,et al.Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide.The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) Study.Circulation,1998,98 (Suppl Ⅰ):Ⅰ-2633.
3Singh SN,Zoble RG,Yellen L,et al.Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation/flutter:the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.Circulation,2000,102:2385-2390.
4Pedersen OD,Bagger H,Keller N,et al.Efficacy of dofetilide in the treatment of atrial fibrillation/flutter in patients with reduced left ventricular function:a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy.Circulation,2001,104:292-296.
5Kober L,Bloch-Thomsen PE,Moller M,et al.Effects of dofetilide in patients with recent myocardial infarction and left ventricular dysfunction:a randomized trial.Lancet,2000,356:2052-2058.
6Bianconi L,Castro A,Dinelli M,et al.Comparison of intravenously administered dofetilide versus amiodarone in acute termination of atrial fibrillation and flutter.A multicentre randomized double-blind placebo-controlled trial.Eur Heart J,2000,21:1265-1273.
7Page RL,Tilsch TW,Connolly SJ,et al.for the Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators.Asymptomatic or " Silent" Atrial Fibrillation:Frequency in Untreated Patients and Patients Receiving Azimilide.Circulation,2003,107:1141-1145.
8Camm AJ,Pratt CM,Schwartz PJ,et al.On Behalf of the AzimiLide post Infarct sur Vival Evaluation (ALIVE) Investigators.Mortality in Patients After a Recent Myocardial Infarction:A Randomized,Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification.Circulation,2004,109:990-996.
9Frick M,Deirpo B, Ostergren J, et M. The effect of oral Magnesium, a- lone or as an .adjuvant to sotalol, 'after cardioversinn in patients with per- sistent atrial fibrillation[ J]. Eur Hear J, 2000, 21 ( 14 ) : 1177-1185.
10Oliveira LH, Mallmann FB, Botelho FN, et al. Cross-sectional study of treatment strategies on atrial fibrillation [ J]. Arq Bras Cardiol, 2012, 98(3) : 195-202.
